Drawing for HEMA BIOLOGICS

USPTO serial 87435627

HEMA BIOLOGICS

Reviewed by CopyMark Law Group

Reg. 5435088Status 701Registered
Filing date
Status date
Registration date
Mar 27, 2018
Examiner
JONES, JACQUELYN ANDREA
Law office
TMO LAW OFFICE 120

What this means

Status 701 means the registration is active and the first Section 8 declaration of continued use was accepted. The next major deadline is the combined Section 8 and Section 9 filing at the 10-year anniversary. Calendar the 10-year Section 8 and 9 combined renewal.

Status 701: Status 701 means the registration is active and the first Section 8 declaration of continued use was accepted. The next major deadline is the combined Section 8 and Section 9 filing at the 10-year anniversary.

Need help with HEMA BIOLOGICS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Amy B. Berge

Amy B. Berge Gray Ice Higdon, PLLC4600 Shelbyville Road#8022LOUISVILLE, KY 40257

Goods and services

ClassDescriptionStatusFirst use
042Providing scientific and medical research information in the field of rare blood disordersACTIVEJul 22, 2016

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 12, 2023NAS8NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED—
Sep 12, 20238.OKREGISTERED - SEC. 8 (6-YR) ACCEPTEDThe USPTO accepted your Section 8 declaration showing the mark is still in use in commerce (or excusable nonuse). This satisfies the six-year maintenance requirement and keeps the registration active until the next renewal deadline.
Sep 12, 2023APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Apr 21, 2023ES8RTEAS SECTION 8 RECEIVED—
Mar 27, 2023REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Mar 27, 2018R.SRREGISTERED-SUPPLEMENTAL REGISTERYour mark is registered on the Supplemental Register, which is available for marks that are not yet distinctive enough for the Principal Register but can still identify a source. Protection is more limited than Principal Register registration but can later support a Principal Register application.
Feb 20, 2018PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Feb 16, 2018ALIEASSIGNED TO LIE—
Feb 1, 2018CNTAAPPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER—
Feb 1, 2018XAECEXAMINER'S AMENDMENT ENTERED—
Feb 1, 2018GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Feb 1, 2018GNEAEXAMINERS AMENDMENT E-MAILED—
Feb 1, 2018CNEAEXAMINERS AMENDMENT -WRITTEN—
Aug 7, 2017GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 7, 2017GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 7, 2017CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 31, 2017DOCKASSIGNED TO EXAMINER—
May 10, 2017MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
May 9, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
May 6, 2017NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance